Dendreon's Provenge at the center of CMS insider trading probe

The SEC is investigating whether officials at the Center for Medicare and Medicaid Services (CMS) tipped off a policy research group about the agency's review of Dendreon's ($DNDN) cancer vaccine, Provenge, The Wall Street Journal reports. Dendreon's stock plunged 26% between June 1, 2010, and the close of trading on June 30, just before CMS announced a decision to consider setting coverage limits on the treatment. More (sub. req.)

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.